Zansecimab: meta-analysis of COVID-19 studies

0 0.5 1 1.5+ All studies -36% 1 95 Improvement, Studies, Patients Relative Risk Mortality -36% 1 95 RCTs -36% 1 95 Late -36% 1 95 Zansecimab for COVID-19 c19early.org December 2025 Favorszansecimab Favorscontrol
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Jones (DB RCT) -36% 1.36 [0.51-3.63] death 8/47 6/48 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.55 Late treatment -36% 1.36 [0.51-3.63] 8/47 6/48 36% higher risk All studies -36% 1.36 [0.51-3.63] 8/47 6/48 36% higher risk 1 zansecimab COVID-19 study c19early.org December 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.55 Effect extraction pre-specified(most serious outcome) Favors zansecimab Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Jones (DB RCT) -36% 1.36 [0.51-3.63] 8/47 6/48 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.55 Late treatment -36% 1.36 [0.51-3.63] 8/47 6/48 36% higher risk All studies -36% 1.36 [0.51-3.63] 8/47 6/48 36% higher risk 1 zansecimab COVID-19 mortality result c19early.org December 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.55 Favors zansecimab Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Jones (DB RCT) -36% 1.36 [0.51-3.63] death 8/47 6/48 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.55 Late treatment -36% 1.36 [0.51-3.63] 8/47 6/48 36% higher risk All studies -36% 1.36 [0.51-3.63] 8/47 6/48 36% higher risk 1 zansecimab COVID-19 Randomized Controlled Trial c19early.org December 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.55 Effect extraction pre-specified(most serious outcome) Favors zansecimab Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Jones (DB RCT) -36% 1.36 [0.51-3.63] 8/47 6/48 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.55 Late treatment -36% 1.36 [0.51-3.63] 8/47 6/48 36% higher risk All studies -36% 1.36 [0.51-3.63] 8/47 6/48 36% higher risk 1 zansecimab COVID-19 RCT mortality result c19early.org December 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.55 Favors zansecimab Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Jones (DB RCT) -36% 1.36 [0.51-3.63] death 8/47 6/48 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.55 Late treatment -36% 1.36 [0.51-3.63] 8/47 6/48 36% higher risk All studies -36% 1.36 [0.51-3.63] 8/47 6/48 36% higher risk 1 zansecimab COVID-19 peer reviewed studies c19early.org December 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.55 Effect extraction pre-specified(most serious outcome) Favors zansecimab Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Jones (DB RCT) -36% 1.36 [0.51-3.63] death 8/47 6/48 Improvement, RR [CI] Treatment Control Jones (DB RCT) -79% 1.79 [0.56-5.71] death 7/47 4/48 Jones (DB RCT) -70% 1.70 [0.67-4.31] death/int. 10/47 6/48 Zansecimab COVID-19 outcomes c19early.org December 2025 Favors zansecimab Favors control